Trials / Completed
CompletedNCT00174408
Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age
Growth Hormone Treatment in Short Children Born Small for Date (Genotonorm)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 3 Years – 7 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in short children born SGA. Safety of the drug is a main objective as well. The growth promoting effect of two different dosages is compared. The effect of long-term treatment on final height is evaluated (according to several amendments)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genotropin |
Timeline
- Start date
- 1990-03-01
- Completion
- 2005-02-01
- First posted
- 2005-09-15
- Last updated
- 2007-05-03
Source: ClinicalTrials.gov record NCT00174408. Inclusion in this directory is not an endorsement.